becton dickinson compani
summari host manag healthcar
confer believ manag good line sight
key busi confid deliv top-lin growth
takeaway meet includ follow
exist contract order alreadi hand ps give
manag confid sale grow
peripher intervent growth momentum appear sustain
support underappreci dialysi portfolio tva
medic covera lutonix av arterioven fistula lutonix
btk knee file latter expect end
sep bcr deal integr remain track includ
combin ex-fx revenu growth high-singl digit earn
accret swatch patch pump file expect
end sep launch like late continu commerci
ramp sever recent launch drive continu growth
momentum bd lifesci see guidanc
somewhat conserv headwind like fx
rise resin cost manag hope off-set much
impact done histor believ bdx sale
growth momentum continu next year help drive mid-
teen underli ep growth rais price target
base blend price-to-earnings ev/ebitda multipl reflect
seem confid sale growth acceler
deliv ytd underli sale growth ex-fx puerto
rico us dispens chang expect growth acceler
anticip growth acceler driven
medic manag solut ps pharma system
lesser extent surgeri compani expect
ps sale grow double-digit manag
confid outlook base good line site
demand pipelin base exist contract order alreadi
hand addit compani expect strong gross
margin momentum vs continu
especi mix contribut bcr
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
includ bcr acquisit start
compani data secur llc estim reuter
continu previou page
see multipl driver behind growth outlook exclud impact us dispens chang
sale grew ytd compani believ growth could acceler
double-digit base exist contract order alreadi hand expect growth
momentum continu beyond driven pyxi alari complet us dispens
chang bdx salesforc focu drive increment softwar util revenu
opportun beyond capit placement pyxi system addit compani believ
newli launch alari pump system remain market leader hold twice market share next
closest competitor believ fulli integr larg volum infus syring pca patient
control analges pump system repres competit advantag integr addit
softwar medic dispens electron medic record offer differenti
bd intervent growth driven peripher momentum improv surgeri bd
intervent sale grew ytd expect growth rel stabl impli
guidanc approxim much ytd strength peripher intervent pi
grew first three quarter expect pi growth remain high-singl
digit even anniversari lutonix av arterioven access launch driven part
expand dialysi portfolio like lutonix btk launch compani track file lutonix btk
end septemb expect launch product later data btk trial expect
medic meet around end earli believ remain optimist
btk approv surgeri ytd growth depress impact hurrican maria
absenc progel expect growth surgeri return histor solid mid-singl digit
beyond hernia mesh product relaunch puerto rico progel expect
return
expand dialysi franchis underappreci meet manag review
grow dialysi portfolio focus creat maintain restor av fistula dialysi
patient continu view underappreci opportun product repres
coupl hundr million dollar opportun time acquir tva medic juli
launch everlinq system first endovascular devic creat av fistula manag believ
everlinq offer meaning advantag dialysi access compar current invas
procedur bdx recent approv covera cover stent intend help maintain av fistula
lutonix help restor fistula
bcr integr track deal metric unchang includ combin revenu growth
manag believ bcr integr track slightli ahead plan underli bcr
busi well ytd growth ex-hurrican revenu synergi front
scale biosurgeri salesforc europ recent complet integr bcr picc
bdx midline/cathet busi drive cross-sel opportun compani continu expect
bcr revenu synergi start materi magnitud greater ten
bp initi cfn revenu synergi expect guid combin ex-fx sale growth
consist manag expect bcr deal announc compani
continu expect cost synergi first three year post-clos driven reduc public
compani cost system/process integr manufactur efficiencies/consolid effort
still expect yield underli margin improv year track pay
anoth debt year-end total year reach
diabet updat swatch file year-end complet clinic test swatch patch
pump type diabet plan file fda approv approv expect
toward end swatch intend replac multi-daili injector repres
multi-hundr million dollar market opportun compani hope launch swatch robust
data set support price that equival tradit insulin pen therapi key benefit
swatch abl deliv basal bolu insulin therebi reduc price
insulin use enabl better asp devic contrast current patch pump deliv basal
insulin pen supplement need bolu insulin regard infus set sens
bdx/mdt still work product redesign expect return market
bd lifesci ls growth momentum continu guidanc may prove conserv
estim bd ls sale grew ytd includ benefit strong
flu season even exclud flu benefit underli growth still close closer
adjust manufactur issu pa preanalyt system manag highlight strong
perform driven new launch pa bioscienc kiestra bd max diagnost
growth guidanc repres deceler believ conservat
built outlook new presid bd ls patrick kaltenbach expect focu leverag
technolog acceler develop rapid diagnost test
becton dickinson compani
expect sale growth momentum continu believ bdx underli
sale growth momentum continu especi bcr revenu synergi expect
start materi expect increment revenu new product launch solid growth
momentum base busi partli off-set headwind fx flu benefit
bottom-lin manag affirm high-singl digit bcr earn accret mid-teen
underli ex-fx ep growth howev headwind like fx rise resin price china tariff
could put pressur margin report ep growth next year manag hope off-set
much headwind compani abl histor
price target
price target base blend ev/ebitda ebitda price-to-earnings
estim risk includ slower expect integr bcr lower expect cost save
accret bcr unexpect delay debt pay unexpect pipelin delay/setback
believ well posit acceler top- bottom-lin growth bcr acquisit
potenti upsid
global medic devic compani oper two key segment medic life
scienc pend bcr acquisit add third leg platform intervent grew
revenu pro forma ex-fx basi
